Treating ALK-positive lung cancer-early successes and future challenges

被引：200

作者：

Camidge, D. Ross ^{[1
]}

Doebele, Robert C. ^{[1
]}

机构：

[1] Univ Colorado, Div Med Oncol, Ctr Canc, Aurora, CO 80045 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2012年 / 9卷 / 05期

关键词：

ANAPLASTIC LYMPHOMA KINASE; RECEPTOR TYROSINE KINASE; GASTROINTESTINAL STROMAL TUMORS; EML4-ALK FUSION GENE; GROWTH-FACTOR; ACTIVATING MUTATIONS; CLINICAL RESISTANCE; ONCOGENIC MUTATIONS; ACQUIRED-RESISTANCE; CELL LYMPHOMA;

D O I：

10.1038/nrclinonc.2012.43

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur infrequently in non-small-cell lung cancer (NSCLC), but provide an important paradigm for oncogene-directed therapy in this disease. Crizotinib, an orally bioavailable inhibitor of ALK, provides significant benefit for patients with ALK-positive (ALK+) NSCLC in association with characteristic, mostly mild, toxic effects, and this drug has been approved by the FDA for clinical use in this molecularly defined subgroup of lung cancer. Many new ALK inhibitors are being developed and understanding the challenges of determining and addressing the adverse effects that are likely to be ALK specific, while maximizing the time of benefit on targeted agents, and understanding the mechanisms that underlie drug resistance will be critical in the future for informing the optimal therapy of ALK+ NSCLC.

引用

页码：268 / 277

页数：10

共 97 条

[71] Crizotinib and Testing for ALK [J].

Shaw, Alice T. ;

Solomon, Benjamin ;

Mino-Kenudson, Mari .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (12) :1335-1341

[72] Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis [J].

Shaw, Alice T. ;

Yeap, Beow Y. ;

Solomon, Benjamin J. ;

Riely, Gregory J. ;

Gainor, Justin ;

Engelman, Jeffrey A. ;

Shapiro, Geoffrey I. ;

Costa, Daniel B. ;

Ou, Sai-Hong I. ;

Butaney, Mohit ;

Salgia, Ravi ;

Maki, Robert G. ;

Varella-Garcia, Marileila ;

Doebele, Robert C. ;

Bang, Yung-Jue ;

Kulig, Kimary ;

Selaru, Paulina ;

Tang, Yiyun ;

Wilner, Keith D. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Iafrate, A. John ;

Camidge, D. Ross .

LANCET ONCOLOGY, 2011, 12 (11) :1004-1012

[73] Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK [J].

Shaw, Alice T. ;

Yeap, Beow Y. ;

Mino-Kenudson, Mari ;

Digumarthy, Subba R. ;

Costa, Daniel B. ;

Heist, Rebecca S. ;

Solomon, Benjamin ;

Stubbs, Hannah ;

Admane, Sonal ;

McDermott, Ultan ;

Settleman, Jeffrey ;

Kobayashi, Susumu ;

Mark, Eugene J. ;

Rodig, Scott J. ;

Chirieac, Lucian R. ;

Kwak, Eunice L. ;

Lynch, Thomas J. ;

Iafrate, A. John .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4247-4253

[74] A Gene Expression Signature Associated with "K-Ras Addiction" Reveals Regulators of EMT and Tumor Cell Survival [J].

Singh, Anurag ;

Greninger, Patricia ;

Rhodes, Daniel ;

Koopman, Louise ;

Violette, Sheila ;

Bardeesy, Nabeel ;

Settleman, Jeff .

CANCER CELL, 2009, 15 (06) :489-500

[75] Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer [J].

Soda, Manabu ;

Choi, Young Lim ;

Enomoto, Munehiro ;

Takada, Shuji ;

Yamashita, Yoshihiro ;

Ishikawa, Shunpei ;

Fujiwara, Shin-ichiro ;

Watanabe, Hideki ;

Kurashina, Kentaro ;

Hatanaka, Hisashi ;

Bando, Masashi ;

Ohno, Shoji ;

Ishikawa, Yuichi ;

Aburatani, Hiroyuki ;

Niki, Toshiro ;

Sohara, Yasunori ;

Sugiyama, Yukihiko ;

Mano, Hiroyuki .

NATURE, 2007, 448 (7153) :561-U3

[76] Are Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer Prognostic, Predictive, or Both? [J].

Solomon, Benjamin ;

Shaw, Alice T. .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (01) :5-7

[77] Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway [J].

Souttou, B ;

Brunet-De Carvalho, N ;

Raulais, D ;

Vigny, M .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (12) :9526-9531

[78] Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [J].

Spigel, D. R. ;

Ervin, T. J. ;

Ramlau, R. ;

Daniel, D. B. ;

Goldschmidt, J. H. ;

Blumenschein, G. R. ;

Krzakowski, M. J. ;

Robinet, G. ;

Clement-Duchene, C. ;

Barlesi, F. ;

Govindan, R. ;

Patel, T. ;

Orlov, S. V. ;

Wertheim, M. S. ;

Zha, J. ;

Pandita, A. ;

Yu, W. ;

Yauch, R. L. ;

Patel, P. H. ;

Peterson, A. C. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[79] Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types [J].

Stoica, GE ;

Kuo, A ;

Powers, C ;

Bowden, ET ;

Sale, EB ;

Riegel, AT ;

Wellstein, A .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (39) :35990-35998

[80] Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin [J].

Stoica, GE ;

Kuo, A ;

Aigner, A ;

Sunitha, I ;

Souttou, B ;

Malerczyk, C ;

Caughey, DJ ;

Wen, DZ ;

Karavanov, A ;

Riegel, AT ;

Wellstein, A .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (20) :16772-16779

← 1 2 3 4 5 6 7 8 9 10 →